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Here we provide a brief “primer” to assist healthcare providers in
correcting a growing body of misinformation surrounding COVID-19
vaccines.
To date, just over 100 million COVID-19 immunizations have been
administered, led by the United States accounting for more than one-
third (35 million), followed by China (24 million) and the European
Union (14 million). In 2020, up to one-third or more of people sur-
veyed both globally and in the United States indicated they might
refuse the first COVID-19 vaccines when released through emergency
use authorization (EUA). Their rationale included questions about
vaccine efficacy, potential side effects, or speeding through* Corresponding author:
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rates of COVID-19 vaccine hesitancy were noted [1]. Another issue is
the politicization of COVID-19 vaccines, or suspicions circulating in
the African American community linked to structural racism and his-
torical experiences with the biomedical community [2,3]. Thus, while
overall vaccine confidence may be increasing in some countries glob-
ally [4], the opposite might be happening regarding COVID-19 vacci-
nation confidence. Currently, organizations dedicated to antivaccine
activities exploit COVID-19 vaccine hesitancy to fuel discord or dis-
credit vaccine efficacy and safety [5]. Ultimately, halting transmission
may require at least 7080% vaccine coverage [6].
Rushing Vaccines: Reporting global efforts to develop COVID-19
vaccines as a “race” while tying it to national identities or imbuing
the US COVID-19 vaccine program with Star Trek imagery were not
helpful. For years, a central but false tenet of the antivaccine lobby
has been that vaccines are not adequately tested for safety. In both
the US and internationally, phase 3 trials were well-powered studies
of 30,000 to 60,000 human volunteers, equivalent to other large vac-
cine clinical trials required to license vaccines [7].
An “average vaccine” requires a 10.7-year timeline beginning with
the preclinical phase [7], whereas COVID-19 vaccine programs may
complete clinical testing leading to EUA in less than a year. However,
the research on COVID-19 vaccines did not first begin in 2020, butr the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
2 P. Hotez et al. / EClinicalMedicine 33 (2021) 100780instead built on a decade of previous research on coronaviruses, lead-
ing to proof-of-concept for the spike protein as a lead vaccine target.
Therefore, when Chinese scientists placed the SARS-2 coronavirus
genomic sequence on preprint servers in January 2020, it was possi-
ble to quickly adapt previous vaccine concepts to this new virus path-
ogen. A second accelerant was the use of new mRNA and adenovirus
technologies allowing a fast turnaround time from elucidating the
genomic sequence to making early prototype vaccines. A third and
bona fide speed component was building factories for vaccine
manufacturing in parallel with clinical testing. Known as manufactur-
ing “at risk”, this is in contrast to traditional approaches in which vac-
cines might typically go through full approval before embarking on
manufacture. Finally, the first COVID-19 vaccines are already being
released through EUA mechanisms due to the lengthy time often
required for formal approval of a biologics license application (BLA).
American, European, and British national regulatory authorities
undertook extensive measures to approximate full BLA approval both
in terms of adequately assessing COVID-19 vaccines for efficacy and
safety, and inspection of vaccine manufacturing facilities. Ultimately,
the COVID-19 vaccines are expected to complete the full licensure
process.
Health freedom: An emerging anxiety is a fear that mandates or
forced vaccinations might be imminent globally. In the US, “health
freedom” objections against vaccines required for school entry accel-
erated beginning in 2015, especially in California and Texas [5]. This
led to significant increases in vaccine exemptions culminating in
measles epidemics. In 2020, health freedom movements expanded to
include protests against social distancing and face masks, eventually
extending to Western European capitals hosting large anti-vaccine
and anti-mask rallies [5]. Currently, no COVID-19 vaccination man-
dates are anticipated for the general or civilian public [8], although
we cannot exclude potential downstream requirements for military
personnel or for some college or university students living dormito-
ries, similar to some mandates for meningococcal meningitis immu-
nizations.
“Genetically Modified Humans”: The early successes of mRNA
COVID-19 vaccine approaches incited claims from antivaccine groups
that this constitutes genetic manipulation. It alleges vaccination will
insert foreign genes into our genome. Adopting the language from
genetically modified organisms(GMO), vaccine critical groups have
sensationalized the idea of the vaccine creating “genetically modified
humans”(GMH). In fact, the mRNA from these vaccines enters human
cells and translates into polypeptides in the cytoplasm and not the
nucleus. Moreover, while overexpression of LINE-1 or HIV-1 reverse
transcriptase in HEK cell lines in vitro can produce cellular DNA cor-
responding to COVID-19 virus sequences [9], there is no evidence
that this finding has relevance to human clinical medicine.
5 G, Implanting Microchips and thalidomide: One conspiracy claims
that COVID-19 is caused by the new availability of 5 G mobile.
Another claim falsely asserts that COVID-19 vaccines serve as a
device to insert microchips for purposes of tracking or surveillance,
sometimes led by software and computer developers. Another circu-
lating fear is that COVID-19 vaccine trials might result in unintended
consequences similar to the tragedy during the 1950s-60s when the
drug thalidomide was used to treat nausea in early pregnancy.
Fetal Abortions: Two human fetal cell lines are used to produce five
COVID-19 vaccines. They include four vaccines that use HEK-293
cells, a cell line derived from the kidney from a fetus aborted in the
early 1970s, and one using a PER.C6 cell line from an aborted fetus in
1985. These cell lines, used to produce the AstraZeneca Oxford, John-
son & Johnson, and CanSinoBio adenovirus-vectored vaccines have
been propagated for decades and no longer contain remnants of
actual fetal tissue. Vaccines for hepatitis A, rubella, and varicella also
employ similar cell lines. Recently, the Vatican has indicated that the
public health benefits of vaccination outweigh the moral opposition
to vaccines from these cell lines [10].Concluding Remark - It is imperative that government leaders pri-
oritize evidence-driven communication strategies in their COVID-19
vaccine programs, while healthcare providers maintain situational
awareness, respond to public concerns, and counter unfounded
claims by those seeking to undermine public confidence in vaccines.
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